Update shared on 03 Nov 2025
Fair value Increased 4.25%Analysts have raised their price target for Quaker Chemical from $155.40 to $162.00. They cite improved profit margin forecasts and higher projected revenue growth as key factors in the revised valuation.
What's in the News
- Quaker Chemical completed a buyback tranche, repurchasing 29,791 shares between July 1, 2025 and September 30, 2025 for $3.81 million (Key Developments)
- The company has now finished repurchasing 638,901 shares for a total of $85.75 million under its buyback program announced on February 28, 2024 (Key Developments)
Valuation Changes
- Fair Value has increased from $155.40 to $162.00, reflecting a higher assessed company worth.
- Discount Rate has decreased slightly from 8.09% to 8.05%, indicating a modest reduction in perceived risk.
- Revenue Growth is projected to rise from 3.91% to 4.02%, signaling improved expectations for sales expansion.
- Net Profit Margin has strengthened substantially from 25.87% to 60.98%.
- Future P/E ratio has fallen significantly from 5.90x to 2.56x, suggesting a more attractive valuation based on projected earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.